|
|
| Neurologie > Etude de marché sectorielle |
| Disease and Therapy Review: Schizophrenia |
|
|
|
|
€ 720,00 |
Editeur
: |
Timely Data Resources |
Langue
: |
Anglais |
Date de publication : |
Janvier 2007 |
Taille du document : |
8 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 21 pages | Mars 2002 | Anglais
|
|
|
| Main
focus: |
schizophrenia,antidepressant,antipsychotic,...,...
|
| Research
focus: |
market definition,market outlook,strategy, |
| Geographic
focus: |
usa,canada,croatia,united kingdom |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pipeline Insight: Anxiety Disorders - A decade of declining revenues 310 pages | Mars 2006 |
IntroductionThe global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 200615 -6.0%). This will be primarily due to the launch of numerous generic |
9 120,00 €
|
| |
| |
Zoloft Annual Sales, 2000-2006 1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
World Sleep Disorders Market, 2004-2011 1 pages | Mars 2006 |
This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Deals and alliances in central nervous system diseases 1068 pages | Avril 2006 |
Partneringdesk deals and alliances in central nervous system diseases provides an in-depth view of over 1100 deals and alliances announced in central nervous system diseases between 2001 and 2006, in |
1 995,00 €
|
| |
| |
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail to Nail Neuropathic Pain 183 pages | Juillet 2005 |
IntroductionThe neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed. With many drugs now in clinical trials for key neuropathic pain su |
9 120,00 €
|
| |
| |
MarketWatch: CNS 25 pages | Février 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives. It provides monthly insight into the key events in the CNS industry. The report contains the latest news, analys |
160,00 €
|
| |
| |
The World Sleep Disorders Market, 2005-2010 87 pages | Septembre 2005 |
The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% |
2 219,00 €
|
| |
| |
Nutraceuticals - Targeting Consumers Aged 14 –34 146 pages | Septembre 2000 |
The 14-34 age group represents approximately 30% of the total population across the 8 countries covered in the report, and as such are a key target audience. This group is particularly critic |
955,00 €
|
| |
| |
MarketWatch: CNS 28 pages | Juin 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives. It provides monthly insight into the key events in the CNS industry. The report contains the latest news, analys |
160,00 €
|
| |
| |
US State Market Index: Drugs acting on the central nervous system & sense organs 12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Drugs acting on the central nervous system & sense organs [Manufacturing sector], broken out on a state-by-state basis. Analysis is based on da |
475,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Disease and Therapy Review: Schizophrenia |
|
|
The Schizophrenia Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments. Dosing information and treatment costs are provided for a wide range of products. General information is included on the size of the schizophrenia pharmaceutical market, and the impact of upcoming patent expirations.
Additional Information
Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
|
|
I. Overview II. Incidence and Prevalence Incidence Table: (US, Canada, UK, Germany, Japan, India, Worldwide) Prevalence Table: (US, Canada, UK, Italy, Japan, China, India, Worldwide) III. DIAGNOSIS IV. TREATMENT V. DOSING AND TREATMENT COSTS VI. MARKET SIZE VII. COMMENTS VIII. References/Resources
|
|
|
PPLSEN
|
|
|
|
|